Ballast Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ballast Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$39.5K	Buy	309 +14	+5%	+$1.75K	0.01%	232
2025 Q4	$36K	Buy	+295	New	+$33.8K	0.01%	154
2024 Q2	–	Sell	-74	Closed	-$7.02K	–	173
2024 Q1	$7.02K	Hold	74	–	–	﹤0.01%	163
2023 Q4	$6.61K	Sell	74 -51	-41%	-$3.79K	﹤0.01%	160
2023 Q3	$9.13K	Sell	125 -538	-81%	-$43K	﹤0.01%	167
2023 Q2	$55.2K	Sell	663 -295	-31%	-$24.7K	0.02%	146
2023 Q1	$73K	Buy	958 +219	+30%	+$18.2K	0.03%	144
2022 Q4	$61.3K	Hold	739	–	–	0.03%	140
2022 Q3	$59K	Hold	739	–	–	0.03%	137
2022 Q2	$55K	Buy	739 +17	+2%	+$1.28K	0.02%	141
2022 Q1	$65K	Sell	722 -308	-30%	-$28.4K	0.03%	145
2021 Q4	$115K	Hold	1,030	–	–	0.04%	130
2021 Q3	$129K	Sell	1,030 -39	-4%	-$5.02K	0.05%	124
2021 Q2	$145K	Hold	1,069	–	–	0.06%	117
2021 Q1	$145K	Hold	1,069	–	–	0.07%	112
2020 Q4	$150K	Hold	1,069	–	–	0.08%	104
2020 Q3	$119K	Hold	1,069	–	–	0.07%	105
2020 Q2	$120K	Sell	1,069 -80	-7%	-$7.88K	0.09%	101
2020 Q1	$89K	Sell	1,149 -115	-9%	-$10.2K	0.08%	98
2019 Q4	$120K	Buy	+1,264	New	+$109K	0.09%	102

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ballast Advisors's XBI Position: Q1 2026 in Review

Ballast Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 4.7% in Q1 2026, buying an estimated $1.75K and bringing the position to 309 shares worth $39.5K. The position accounts for 0.01% of the portfolio, ranked #232.

Ballast Advisors first reported a position in XBI in Q4 2019 and has held it in 20 quarters since. The position peaked at $150K in Q4 2020. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Ballast Advisors held 309 shares of State Street SPDR S&P Biotech ETF worth $39.5K as of Q1 2026.
Ballast Advisors bought 14 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.75K.
State Street SPDR S&P Biotech ETF made up 0.01% of Ballast Advisors's portfolio in Q1 2026, its #232 holding.
Ballast Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and has held it in 20 quarters since.
Ballast Advisors's State Street SPDR S&P Biotech ETF position peaked at $150K in Q4 2020.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Ballast Advisors's 13F filing for Q1 2026, filed 13 May 2026.